Christy Oliger

Operates as a biotechnology company that develops medicines for cancer peoples

Develops novel therapeutic approaches for cancer and other diseases

Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases

Functions as a College/University

Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation

Develops oncolytic immunotherapies

Operates as a biotechnology company that develops antibodies for the treatment of cancer

Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology.

Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases